What changed
Adjusted EPS of $0.06 came in well below the $0.10 consensus, a 40.0% miss, as the top line printed $1,591M, down 8.7% YoY. Management updated FY2026 adjusted EPS guidance to $0.76-$0.80 and other guidance to $1.1B-$1.1B. The quarter was pressured by pricing declines concentrated in North America (acetochlor) and Latin America, where competitive pressure on molecules late in their lifecycle and weaker Brazil market conditions drove the shortfall.
Why it matters
Adjusted EPS of $0.06 came in well below the $0.10 consensus, a 40.0% miss, as the top line printed $1,591M, down 8.7% YoY. Management updated FY2026 adjusted EPS guidance to $0.76-$0.80 and other gui